The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma

© The Author(s) 2022

Dear Editor,

Multiple myeloma (MM) emerges as a heterogeneous disease with a considerable diversity in tumor biology, clinical characteristics, therapeutic responses, and outcomes in the era of novel agents and therapies (e.g., proteasome inhibitors/PI, immunomodulatory drugs/IMiD, CD38 monoclonal antibodies, etc.) [1]. To guide making treatment decision, multiple risk stratification systems have been developed to discriminate different risk levels of MM patients at diagnosis, including the ISS or its successor R-ISS currently used in clinical practice [2]. The R-ISS was created via updating the ISS by including elevated lactate dehydrogenase (LDH) and high-risk cytogenetic abnormalities (HRCA) such as del(17p), t(4;14), and t(14;16) [3, 4]. However, with the paradigm shift in the treatment of MM, the impact or weight of these and other baseline risk factors in estimating the outcomes of MM patients may have changed [5]. For example, the prognostic impact of some additional HRCA that have not been included in the R-ISS [6, 7], such as +1q including 1q21 gain (3 copies) or amplification (≥ 4 copies) [8, 9], as well as their concurrence in various combinations [10] (so called double- and triple-hit [11]) have been emerging. Moreover, one of the limitations for the R-ISS is that more than a half of patients with newly diagnosed MM (NDMM) have been classified as R-ISS II with intermediate risk, whose outcomes may however vary to a large extent. To address these concerns, two staging systems, including the Mayo Additive Staging System (MASS) and Second Revision of the International Staging System (R2-ISS), have been reported very recently [12, 13].

These two new algorithms have been built on virtually same risk factors that are associated with overall survival (OS; the MASS) or both progression-free survival (PFS) and OS of NDMM patients (the R2-ISS), including ISS III (the R2-ISS II was also scored in the R2-ISS), elevated LDH, del(17p), +1q, and HR IGH translocation [12, 13]. The MASS includes any HR IGH translocation, while the R2-ISS only included t(4;14). Although t(14;16) is demonstrated as an independent adverse factor for OS, it is not included in the R2-ISS because its effect on PFS was not statistically significant [13]. +1q is scored as 1 (same as other HRCA) in the MASS while 0.5 (lower than other HRCA) in the R2-ISS. The MASS stratifies NDMM patients more evenly into MASS I (36%), II (33%), and III (31%) than the R-ISS (17%, 66%, and 17% for R-ISS I, II, and III, respectively) [12]. The performance of the MASS and R2-ISS is comparable in risk stratification of R-ISS I patients to I (70–80%) and II stages (20–30%). The MASS re-stratify R-ISS II patients to MASS I (32%), II (47%), and III (21%), while the R2-ISS discriminates R-ISS II patients with R2-ISS II (38%), III (59%), and IV (3%). Unlike the R2-ISS that re-stratifies R-ISS III patients to R2-ISS III (41%) and IV (59%), all R-ISS III patients remain as MASS III. Nonetheless, the performance of these new staging systems requires further validation, especially considering the dissimilarity of MM patients among different populations.

Here, we sought to test the prognostic value of the MASS by analyzing our clinical retrospective data of patients diagnosed with MM between 27 November 2009 and 20 November 2019 at seven centers nationwide in China. All patients must have baseline information available for the MASS scoring, particularly cytogenetics by FISH that must include the probes for del(17p), 1q+, and HR IGH translocations (t(4;14) and t(14;16)); they must receive novel agents (PI, IMiD, or both) for first-line treatment. According to the MASS that scores each risk factor as 1, patients were divided into three groups, including MASS I (score 0), II (score 1), and III (score ≥ 2) [12]. PFS was defined as the time from diagnosis until disease progression, relapse, or death due to any cause. Patients who did not progress or relapse were censored on the last date when they were seen alive and event free. OS was defined as the time from diagnosis until death due to any cause or last followup. This study was approved by the Institutional Review Board (IRB) of the First Hospital of Jilin University (Approval # 2016-087). All patients had given written informed consent to the use of clinical data according to the Declaration of Helsinki. In this cohort (n = 1005), there were clearly more patients with advanced diseases (e.g., ISS and R-ISS III), large tumor burden (e.g., elevated LDH and β2-MG), and organ involvement (e.g., CRAB), compared to the Mayo cohort (Table 1). Notably, the frequency of +1q was higher (51.8%) in this cohort as we observed earlier in Chinese NDMM patients [14], while del(17p) and HR IGH translocation were comparable between these two cohorts. First-line treatment included PI (51% vs. 31%), IMiD (18% vs. 31%), or both (32% vs. 34%), but much less patients received transplant in this cohort (12% vs. 55%), mostly due to unaffordability. According to the IMWG consensus criteria [15], 114 (12.4%), 207 (22.6%), 244 (26.6%), 235 (25.6%), 58 (6.3%), and 59 (6.4%) patients had sCR, CR, VGPR, PR, MR, and SD, respectively. With median follow-up of 35.5 months (95% CI, 32.8–38.2), median PFS and OS were 25.2 (95% CI, 23.1–27.3) and 53.0 (95% CI, 48.1–57.9) months.

According to the MASS, all patients could be stratified to MASS I with no risk factor (70.16%, II with one risk factor (33.0, 32.8%), and III with ≥ 2 risk factors (505, 50.3%). Compared to the Mayo cohort [12], there were relatively less patients with early stage disease (MASS I) but more patients with late stage disease (MASS III), consistent with the fact that majority of patients had advanced disease in this cohort. For MASS I, II, and III, median PFS was 45.6, 27.4, and 20.3 months; and median OS 88.3, 62.9, and 40.6 months, respectively. For each stage, the outcomes of patients were worse than those in the Mayo cohort, while the differences in both PFS (Fig. 1a) and OS (Fig. 1b) were significant for MASS I vs. II (PFS: HR, 1.732; 95% CI, 1.313–2.284; P < 0.0001; OS: HR, 1.647; 95% CI, 1.120–2.422; P = 0.0111) or II vs. III (PFS: HR, 1.505; 95% CI, 1.256–1.802; P < 0.0001; OS: HR, 1.934; 95% CI, 1.530–2.443; P < 0.0001). Together, these observations support the value of the MASS in risk stratification of NDMM patients at diagnosis and prediction of both PFS and OS.

Received: 15 July 2022 Revised: 1 September 2022 Accepted: 1 September 2022
Published online: 14 September 2022
The MASS seems to stratify patients with intermediate risk (e.g., R-ISS II, accounting for about 60% of patients with heterogeneous outcomes) better than the R-ISS [12]. In 624 R-ISS II patients, the MASS further stratified them to MASS I (95, 15.2%), II (287, 46.0%), and III (242, 38.8%), with median PFS of 44.7, 27.3, and 22.8 months (Fig. 1c), and median OS of 67.0, 57.8, and 47.7 months (Fig. 1d), respectively. The differences in PFS were significant for MASS I vs. II (HR, 1.644; 95% CI, 1.160–2.331; \( P = 0.0052 \)), but not I vs. III (HR, 1.319; 95% CI, 0.826–2.105; \( P = 0.2467 \)). Moreover, the MASS re-stratified R-ISS I patients \( (n = 118) \) to MASS I (75, 63.6%) and II (43, 36.4%), while all R-ISS III patients \( (n = 263) \) were MASS III. Therefore, these observations verify the notion that R-ISS II patients had heterogeneous outcomes, which could, at least in part, be discriminated by the MASS.

The MASS can also been used as a 4-tier staging system [12]. In this case, 1005 patients were stratified into MASS I (170, 16.9%), II (330, 32.8%), III (312, 31%), and IV (193, 19.2), with median PFS of 45.6, 27.4, 21.3, and 15.2 months, and median OS of 88.3, 62.9, 

### Table 1. Comparison of baseline characteristics between two cohorts.

| Characteristics                | Our cohort, \( n \) (%) | Mayo cohort [12] |
|--------------------------------|--------------------------|------------------|
| Age (yrs), median (range)      | 61 (27–89)               | 64 (57–71)       |
| Sex, male                      | 590 (58.7)               | 62%              |
| M protein                       |                          |                  |
| IgG                            | 452 (45.0)               | 62%              |
| IgA                            | 249 (24.8)               | 25%              |
| IgD                            | 61 (6.1)                 | –                |
| LC                             | 215 (21.4)               | 11%              |
| Non/oligosecretory             | 27 (2.7)                 | –                |
| Biclonal                       | 1 (0.0)                  | –                |
| ISS stage                      |                          |                  |
| I                              | 169 (16.8)               | –                |
| II                             | 306 (30.4)               | –                |
| III                            | 530 (52.7)               | 33%              |
| R-ISS stage                    |                          |                  |
| I                              | 118 (11.7)               | 11%              |
| II                             | 624 (62.1)               | 66%              |
| III                            | 263 (26.2)               | 23%              |
| LDH, elevated                  |                          |                  |
| BMPCs, \( \geq 30\% \) \( n = 562 \) | 358 (63.7)               | 50 (30–70)\( ^a \) |
| β2-MG, \( \geq 5.5 \mu g/ml \) \( n = 567 \) | 324 (57.1)               | 32%              |
| Hemoglobin, \( \leq 10 \text{g/dL} \) \( n = 948 \) | 635 (67.0)               | 33%              |
| Calcium, \( \geq 1 \text{mg/dL} \) \( n = 1003 \) | 143 (14.3)               | 11%              |
| Creatinine, \( \geq 2 \text{mg/dL} \) \( n = 1004 \) | 261 (26.0)               | 16%              |
| Bone disease \( n = 963 \)     | 887 (92.1)               | –                |
| Extramedullary lesion \( n = 960 \) | 193 (20.1)               | –                |
| Albumin, \( <3.5 \text{g/dL} \) \( n = 899 \) | 523 (58.2)               | 48%              |
| Platelet, \( <100 \times 10^3/L \) \( n = 1002 \) | 149 (14.9)               | 210 (162–262)\( ^a \) |
| +1q                            | 521 (51.8)               | 31%              |
| del(17p)                       | 113 (11.2)               | 13%              |
| del(13q) \( n = 978 \)         | 412 (42.1)               | 37%\( ^b \)      |
| del(1p) \( n = 413 \)          | 35 (8.5)                 | –                |
| IgH translocation              |                          |                  |
| t(11;14)                       | 130 (12.9)               | 21%              |
| t(4;14)                        | 138 (13.7)               | 10%              |
| t(14;16)                       | 22 (2.2)                 | 4%               |
| First-line treatment           |                          |                  |
| PI                             | 511 (50.8)               | 31%              |
| IMiD                           | 177 (17.6)               | 31%              |
| PI + IMiD                      | 317 (31.5)               | 34%              |
| Transplant                     | 122 (12.1)               | 55%              |

\( ^a \)Median (range).

\( ^b \)Monosomy 13.

LC light chain, BMPCs bone marrow plasma cells, β2-MG β2-macroglobulin, LDH lactate dehydrogenase, PI proteasome inhibitor, IMiD immunomodulatory drug.
Fig. 1  Survival of patients with NDMM based on the MASS. PFS a and OS b in patients (n = 1005) with stage I (total score = 0 point), II (total score = 1 point), and III (total score ≥ 2 points) determined by the 3-tier MASS, in which each high-risk factor (i.e., high-risk IGH translocation, 1q gain/amplification, chromosome 17 abnormality, ISS stage III, or elevated LDH) scored one point. PFS c and OS d in R-ISS II patients (n = 624) with stage I, II, and III determined by the 3-tier MASS. PFS e and OS f in patients (n = 1005) with stage I (total score = 0 point), II (total score = 1 point), III (total score = 2 points), and IV (total score ≥ 3 points) determined by the 4-tier MASS, in which each high-risk factor described above scored one point. PFS g and OS h in R-ISS II patients (n = 624) with stage I, II, III, and IV determined by the 4-tier MASS.
48.7, and 28.7 months, respectively. This 4-tier version of the MASS could further stratify patients with MASS III (3-tier) to III and IV on both PFS (Fig. 1e; HR, 1.485; 95% CI, 1.189–1.854; P = 0.0005) and OS (Fig. 1f; HR,1.890; 95% CI, 1.458–2.450; P < 0.0001). Moreover, it also further stratified R-ISS II patients (n = 624) with MASS III (3-tier) to III (224, 35.9%) and IV (18, 2.9%), with median PFS of 23.3 vs. 15.1 months (Fig. 1g; HR, 1.656; 95% CI, 0.952–2.880; P = 0.0743) and median OS of 48.7 vs. 36.5 months (Fig. 1h; HR, 2.004; 95% CI, 1.063–3.779; P = 0.0317). These findings suggest that the 4-tier MASS might perform better than the 3-tier one in risk stratification, at least in this cohort of NDMM patients with more advanced disease and worse outcomes.

In conclusion, this study provides additional evidence supporting the prognostic value of the MASS in risk stratification of NDMM patients at diagnosis, particularly those with R-ISS II defined by the R-ISS, in an entirely independent cohort involving Chinese patient population. Thus, this new simple additive staging system warrants further attention in future investigation and daily practice.

Peiyu Yang1,2, Fan Zhou3, Yujun Dong4, Guangxun Gao5, Hua Xue6, Xinyue Liang1, Shanshan Yu7, Weliing Xu7, Yanping Ma8, Xiaofei Qin6, Mengyao Li1,8, Yun Dai2,8, and Fengyan Jin6,✉
1Department of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China. 2Laboratory of Cancer Precision Medicine, the First Hospital of Jilin University, Changchun, Jilin, China. 3Department of Hematology and Oncology, Shanghai Jiaotong University Affiliated Hospital, Shanghai, China. 4Department of Hematology, Peking University First Hospital, Beijing, China. 5Department of Hematology, Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi, China. 6Department of Hematology, the Affiliated Hospital of Hebei University, Baoding, Hebei, China. 7Department of Radiology, the First Hospital of Jilin University, Changchun, Jilin, China. 8Department Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
email: daiyun@jlu.edu.cn; fengyanjin@jlu.edu.cn

DATA AVAILABILITY
Original data are available to other investigators upon request.

REFERENCES
1. Kumar SK, Rajkumar V. The multiple myelomas — current concepts in cytogentic classification and therapy. Nat Rev Clin Oncol. 2018;15:409–21. https://doi.org/10.1038/s41571-018-0018-y.
2. van de Donk NWJC, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27. https://doi.org/10.1016/S0140-6736(21)00135-5.
3. Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20. https://doi.org/10.1200/JCO.2005.04.242.
4. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldechmidt H, Rosolino L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9. https://doi.org/10.1200/JCO.2015.61.2267.
5. Corre J, Munshi NC, Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a revision? Blood. 2021;137:16–9. https://doi.org/10.1182/blood.2019004309.
6. Perrot A, Lauwers-Cancès V, Tournay E, Hulin C, Chretien M-L, Royer B, et al. Development and validation of a cytogentic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37:1657–65. https://doi.org/10.1200/JCO.18.00776.
7. Atrash S, Flahavan EM, Xu T, Ma E, Karve S, Hong W-J, et al. Treatment patterns and outcomes according to cytogentic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer J. 2022;12:46. https://doi.org/10.1038/s41408-022-00638-0.
8. Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4:3309–19. https://doi.org/10.1182/bloodadvances.2020022118.
9. Weinhold N, Salwender HJ, Cairns DA, Raab MS, Waldron G, Blau IW, et al. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2596 trial patients. Haematologica. 2021;106:2754–8. https://doi.org/10.3324/haematol.2021.278888.
10. Minguela A, Vasco-Mogorrón MA, Campillo JA, Cabañas V, Remigia MJ, Berenguer M, et al. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogentic abnormalities and first-line treatment. Am J Cancer Res. 2021;11:4438–54.
11. Garfield A, Voloshin S, Shuavey S, Martynekvich I, Kleina E, Chechetkin et al. Significance of modified risk stratification mSmart 3.0 and autolologus stem cell transplantation for patients with newly diagnosed multiple myeloma. Blood. 2019;134:5593.
12. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12:21. https://doi.org/10.1038/s41408-022-00611-x.
13. D’Agostino M, Caans DA, Lahuerta J-J, Weller R, Waage A, Bertsch U, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;JCO2102614. https://doi.org/10.1200/JCO.21.02614.
14. Jin F, Gao G, Dong Y, Li C, Huang W, Zhang L, et al. A multi-center epidemiological and prognostic analysis of cytogentic abnormalities in a cohort of 1015 Chinese patients with newly-diagnosed multiple myeloma. Blood. 2019;134:3094. https://doi.org/10.1182/blood-2019-132076.
15. Kumar S, Paiwa B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6.

ACKNOWLEDGEMENTS
This work was supported by the National Natural Science Foundation of China (Grant # 81471165, 81670190, and 81971108 for FJ; 81670189, 81870160, and 82270207 for YDai) and Science and Technology Development Program of the Jilin Province (Grant # 20190201042JC and 20210509010RQ for FJ; 20190201163JC for YDai), and Interdisciplinary Integration and Innovation Project of Jilin University (for FJ).

AUTHOR CONTRIBUTIONS
PY patient care, data review, and statistics; FZ, YDon, GG, XH, XL, SY, WX, YMQ, and ML patient care and data recording; YDai study design, data review, statistics, data interpretation, and writing; FJ study design, patient care, data review and interpretation, writing. Authors met all four criteria for authorship in the ICMJE Recommendations. All authors approved the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Yun Dai or Fengyan Jin.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022